# Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

Study · id `cardio:ct-nct05230901` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05230901](<https://clinicaltrials.gov/study/NCT05230901>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05230901

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

## Technical summary

Registry record NCT05230901. Randomized; no masking; primary purpose treatment. Start 2022-02-23 (actual); primary completion 2025-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT05230901, source copy `cardio:ctgov-nct05230901-2022-06-28`, retrieved 2026-10-26)
- Started: 2022-02-23 (actual) (ClinicalTrials.gov record NCT05230901, source copy `cardio:ctgov-nct05230901-2022-06-28`, retrieved 2026-10-26)
- Primary completion: 2025-06 (anticipated) (ClinicalTrials.gov record NCT05230901, source copy `cardio:ctgov-nct05230901-2022-06-28`, retrieved 2026-10-26)
- Completion: 2026-03 (anticipated) (ClinicalTrials.gov record NCT05230901, source copy `cardio:ctgov-nct05230901-2022-06-28`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT05230901, source copy `cardio:ctgov-nct05230901-2022-06-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05230901-2022-06-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden
- Acronym: Reduce-MFA
- Condition: Aortic Stenosis, Severe
- Intervention (Other): Standard of Care
- Intervention (Drug): Spironolactone 25mg
- Intervention (Drug): Dihydralazine
- Lead sponsor: University Medical Center Goettingen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 3a9ae49d55ef33d8b3efe060034a5e3f6d115b81f9738381099a22bde6a9dbdc
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
